Skip to main content
. 2015 Sep 14;2015:175497. doi: 10.1155/2015/175497

Table 2.

Cell lines used in the evaluation of antiproliferative activity.

Cell line Organ/disease Origin tissue Total growth inhibition (µg/mL)
CE DOX
U251 CNS; glioma Ectoderm 26.10 <0.025
UACC-62 Skin; melanoma Ectoderm 7.30 0.028
NCI-ADR/RES Ovary; adenocarcinoma Ectoderm 26.40 >25.00
786-O Kidney; adenocarcinoma Mesoderm 28.00 0.038
NCI-H460 Lung; non-small-cell lung carcinoma Mesoderm 27.50 <0.025
PC-3 Prostate; adenocarcinoma Mesoderm 24.80 0.025
OVCAR-3 Ovary; adenocarcinoma Mesoderm 4.40 0.230
HT-29 Colon; adenocarcinoma Endoderm 7.90 0.026
K562 Bone marrow; chronic myeloid leukemia Mesenchyme >250 >25.00

Results are the mean ± SD of 3 replicates per treatment in three independent tests after 48 hours of treatment.

CE: crude extract of Amphipterygium adstringens.

DOX: doxorubicin (positive control).

Multidrug resistant cell line.